Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems

Masatoshi Maeki; Niko Kimura; Yusuke Sato; Hideyoshi Harashima; Manabu Tokeshi

doi:10.1016/j.addr.2018.03.008

Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems

Adv Drug Deliv Rev. 2018 Mar 15:128:84-100. doi: 10.1016/j.addr.2018.03.008. Epub 2018 Mar 19.

Authors

Masatoshi Maeki¹, Niko Kimura², Yusuke Sato³, Hideyoshi Harashima³, Manabu Tokeshi⁴

Affiliations

¹ Division of Applied Chemistry, Faculty of Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo 060-8628, Japan. Electronic address: m.maeki@eng.hokudai.ac.jp.
² Graduate School of Chemical Sciences and Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo, Japan.
³ Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12 Nishi 6, Kita-ku, Sapporo 060-0812, Japan.
⁴ Division of Applied Chemistry, Faculty of Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo 060-8628, Japan; ImPACT Research Center for Advanced Nanobiodevices, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan; Innovative Research Center for Preventive Medical Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan; Institute of Innovation for Future Society, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan. Electronic address: tokeshi@eng.hokudai.ac.jp.

PMID: 29567396
DOI: 10.1016/j.addr.2018.03.008

Abstract

Lipid-based nanobiomaterials as liposomes and lipid nanoparticles (LNPs) are the most widely used nanocarriers for drug delivery systems (DDSs). Extracellular vesicles (EVs) and exosomes are also expected to be applied as DDS nanocarriers. The performance of nanomedicines relies on their components such as lipids, targeting ligands, encapsulated DNA, encapsulated RNA, and drugs. Recently, the importance of the nanocarrier sizes smaller than 100nm is attracting attention as a means to improve nanomedicine performance. Microfluidics and lab-on-a chip technologies make it possible to produce size-controlled LNPs by a simple continuous flow process and to separate EVs from blood samples by using a surface marker, ligand, or electric charge or by making a mass or particle size discrimination. Here, we overview recent advances in microfluidic devices and techniques for liposomes, LNPs, and EVs and their applications for DDSs.

Keywords: Drug delivery; Exosome; Extracellular vesicle; Lipid nanoparticle; Liposome; Microfluidic device; Microfluidics; Separation.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Drug Delivery Systems*
Extracellular Vesicles / chemistry*
Humans
Lipids / chemistry*
Microfluidic Analytical Techniques* / instrumentation
Models, Molecular
Molecular Structure
Nanoparticles / chemistry*

Substances

Lipids